Judge OKs Glaxo's $75M Settlement Over Alleged Relafen Evergreening

Law360, New York (December 2, 2004, 12:00 AM EST) -- A federal judge has tentatively approved a $75 million settlement agreement between GlaxoSmithKline PLC and a group of consumers and third-party payors who claimed the U.K. drug maker broke antitrust law by trying to block generic competition for the arthritis drug Relafen.

U.S. District Court Judge William G. Young of the U.S. District Court for the District of Massachusetts last week granted preliminary approval of the proposed settlement, which was announced in May, according to Hagens Berman LLP, a law firm specializing in class-action lawsuits....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.